Your browser doesn't support javascript.
loading
Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination.
Adams, Lily E; Leist, Sarah R; Dinnon, Kenneth H; West, Ande; Gully, Kendra L; Anderson, Elizabeth J; Loome, Jennifer F; Madden, Emily A; Powers, John M; Schäfer, Alexandra; Sarkar, Sanjay; Castillo, Izabella N; Maron, Jenny S; McNamara, Ryan P; Bertera, Harry L; Zweigert, Mark R; Higgins, Jaclyn S; Hampton, Brea K; Premkumar, Lakshmanane; Alter, Galit; Montgomery, Stephanie A; Baxter, Victoria K; Heise, Mark T; Baric, Ralph S.
Afiliação
  • Adams LE; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Leist SR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Dinnon KH; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • West A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Gully KL; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Anderson EJ; Division of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Loome JF; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Madden EA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Powers JM; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Schäfer A; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Sarkar S; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Castillo IN; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Maron JS; Ragon Institute of MGH, MIT, and Harvard University, Cambridge, MA, USA.
  • McNamara RP; Ragon Institute of MGH, MIT, and Harvard University, Cambridge, MA, USA.
  • Bertera HL; Ragon Institute of MGH, MIT, and Harvard University, Cambridge, MA, USA.
  • Zweigert MR; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Higgins JS; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Hampton BK; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Premkumar L; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Alter G; Ragon Institute of MGH, MIT, and Harvard University, Cambridge, MA, USA.
  • Montgomery SA; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Dallas Tissue Research, Dallas, TX, USA.
  • Baxter VK; Division of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Heise MT; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hill,
  • Baric RS; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hi
Cell Rep ; 42(4): 112326, 2023 04 25.
Article em En | MEDLINE | ID: mdl-37000623
ABSTRACT
Group 2B ß-coronaviruses (sarbecoviruses) have caused regional and global epidemics in modern history. Here, we evaluate the mechanisms of cross-sarbecovirus protective immunity, currently less clear yet important for pan-sarbecovirus vaccine development, using a panel of alphavirus-vectored vaccines covering bat to human strains. While vaccination does not prevent virus replication, it protects against lethal heterologous disease outcomes in both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clade 2 bat sarbecovirus challenge models. The spike vaccines tested primarily elicit a highly S1-specific homologous neutralizing antibody response with no detectable cross-virus neutralization. Rather, non-neutralizing antibody functions, mechanistically linked to FcgR4 and spike S2, mediate cross-protection in wild-type mice. Protection is lost in FcR knockout mice, further supporting a model for non-neutralizing, protective antibodies. These data highlight the importance of FcR-mediated cross-protective immune responses in universal pan-sarbecovirus vaccine designs.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Quirópteros / Alphavirus / Coronavírus Relacionado à Síndrome Respiratória Aguda Grave / COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Quirópteros / Alphavirus / Coronavírus Relacionado à Síndrome Respiratória Aguda Grave / COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article